Update to improve reproducibility and interpretability: A response to "Machine Learning for Tumor Growth Inhibition" by Phyllis Chan, James Lu, René Bruno, Jin Y. Jin

Connect to this object online.

Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer by Antonio Gonçalves, Mathilde Marchand, Phyllis Chan, Jin Y. Jin, Jérémie Guedj, René Bruno

Connect to this object online.

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches by Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y. Jin, Jérémie Guedj, René Bruno

Connect to this object online.

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel by Sreenath M. Krishnan, Lena E. Friberg, René Bruno, Ulrich Beyer, Jin Y. Jin, Mats O. Karlsson

Connect to this object online.

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time by Ida Netterberg, René Bruno, Ya‐Chi Chen, Helen Winter, Chi‐Chung Li, Jin Y. Jin, Lena E. Friberg

Connect to this object online.

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework by Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang, Alyse Lin, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y. Jin, René Bruno

Connect to this object online.

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) by Solange Peters, Peter R. Galle, Coen A. Bernaards, Marcus Ballinger, René Bruno, Valerie Quarmby, Jane Ruppel, Alexandr Vilimovskij, Benjamin Wu, Nitzan Sternheim, Martin Reck

Connect to this object online.

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis by Anita Moein, Tong Lu, Siv Jönsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina Tang, Young S. Oh, Rene Bruno, Rui Zhu

Connect to this object online.

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden by Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno

Connect to this object online.

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1) by Benjamin Wu, Nitzan Sternheim, Priya Agarwal, Julia Suchomel, Shweta Vadhavkar, Rene Bruno, Marcus Ballinger, Coen A. Bernaards, Phyllis Chan, Jane Ruppel, Jin Jin, Sandhya Girish, Amita Joshi, Valerie Quarmby

Connect to this object online.